Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1600 1648 1671
This examiner grants 71% of resolved cases
Benjamin P. Blumel is an examiner in Tech Center 1600, specifically assigned to Art Unit 1600. He has a high volume of 1040 resolved cases, making his performance metrics very stable and reliable. His extensive record suggests a high level of experience in the examination process. The 1040 resolved cases provide a substantial dataset for practitioners to analyze.
The examiner has an allowance rate of 70.8 percent. This is a favorable rate for applicants, with nearly three-quarters of cases resulting in a grant. The median days to allowance is 1154, which is a standard timeline for Tech Center 1600. The 70.8 percent allowance rate indicates that the examiner is generally receptive to well-supported claims. Practitioners can use the 1154 median days to allowance to forecast the duration of the prosecution cycle.
The interview lift is 30.5 percent. This is a significant lift, showing that interviews are an effective way to advance prosecution compared to the baseline allowance rate of 70.8 percent. When an interview is conducted, the chances of securing an allowance increase substantially. Practitioners should take advantage of this by scheduling interviews to resolve outstanding issues, as the 30.5 percent lift suggests the examiner is responsive to this form of engagement. This strategy can help maintain the efficiency of the prosecution and capitalize on the 70.8 percent allowance rate.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18016497 | VIRAL DETECTION SYSTEMS AND USES THEREOF | Non-Final OA | TRUSTEES OF BOSTON UNIVERSITY |
| 18850029 | HYDROGEL FORMULATIONS FOR VLP THERAPEUTICS | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18166743 | MANNOSE CONJUGATED CHITOSAN-BASED INFLUENZA NANOVACCINE FORMULATIONS AND USES THEREOF | Non-Final OA | Ohio State Innovation Foundation |
| 18282991 | FLUOROGENIC SENSORS FOR DETECTING ANTIGENS | Non-Final OA | President and Fellows of Harvard College |
| 18037454 | METHODS FOR DETECTING VIRAL RNA USING ATP-RELEASING NUCLEOTIDES | Final Rejection | The Board of Trustees of the Leland Stanford Junior University |
| 17773519 | GOLD NANOPARTICLES/NANOSHELLS IMMUNE CONJUGATES FOR ENHANCED IMMUNOTHERAPY AND PHOTOTHERMAL THERAPY FOR HEMATOLOGIC MALIGNANCIES | Final Rejection | Northwestern University |
| 17965148 | Assay to Differentiate Natural CMV Infection from CMV Vaccines that Lack UL144 | Final Rejection | The Medical College of Wisconsin, Inc. |
| 18643793 | MOLECULAR VACCINES FOR INFECTIOUS DISEASE | Final Rejection | Agilent Technologies, Inc. |
| 18076315 | OMICRON SARS-COV-2 ASSAY | Final Rejection | Board of Regents, The University of Texas System |
| 18749120 | ADENOVIRAL VECTOR SYSTEM FOR GENE DELIVERY | Non-Final OA | Purdue Research Foundation |
| 18557879 | ARTIFICIAL ADJUVANT VECTOR CELL CAPABLE OF INDUCING IMMUNE RESPONSE TO CORONAVIRUS, PHARMACEUTICAL COMPOSITION CONTAINING SAID CELL, AND USE APPLICATIONS OF SAID CELL AND SAID PHARMACEUTICAL COMPOSITION | Non-Final OA | RIKEN |
| 18660408 | VIRUS PURIFICATION METHOD | Non-Final OA | AGC INC. |
| 17760180 | POLYPEPTIDES AND THEIR USE | Final Rejection | University of Washington |
| 17916323 | INFLUENZA VACCINES | Final Rejection | Cambridge Enterprise Limited |
| 18463099 | IMMUNOGENIC COMBINATION COMPOSITIONS AND USES THEREOF | Final Rejection | GLAXOSMITHKLINE BIOLOGICALS SA |
| 18751109 | EFFICIENT VACCINE | Non-Final OA | VLP Therapeutics Japan, Inc. |
| 18067358 | EFFICIENT VACCINE | Non-Final OA | VLP Therapeutics Japan, INC. |
| 18739986 | AAV Vectors | Final Rejection | Vigeneron GmbH |
| 18582939 | OPTIMIZED VECTOR FOR DELIVERY IN MICROBIAL POPULATIONS | Non-Final OA | Institut Pasteur |
| 18164313 | Peptides and Combinations of Peptides for Use in Immunotherapy Against an Infection by Sars-COV-2 (COVID-19) | Non-Final OA | Eberhard Karls Universität Tübingen Medizinische Fakultät |
| 17638750 | PHARMACEUTICAL COMPOSITION FOR TREATING CANCER, COMPRISING VACCINIA VIRUS AND GRANULOPOIESIS INHIBITOR AS ACTIVE INGREDIENTS | Non-Final OA | Bionoxx Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy